These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29552922)

  • 1. [Three decades of the hepatitis C virus from the discovery to the potential global elimination: the success of translational researches].
    Pár A; Pár G
    Orv Hetil; 2018 Mar; 159(12):455-465. PubMed ID: 29552922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatitis C: From Individual Cure to Worldwide Elimination?].
    Boettler T; Lohmann V; Bartenschlager R
    Dtsch Med Wochenschr; 2019 Apr; 144(8):535-542. PubMed ID: 30986861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C: global epidemiology and strategies for control.
    Lanini S; Easterbrook PJ; Zumla A; Ippolito G
    Clin Microbiol Infect; 2016 Oct; 22(10):833-838. PubMed ID: 27521803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of hepatitis C in Europe: can WHO targets be achieved?
    Matičič M; Lombardi A; Mondelli MU; Colombo M;
    Clin Microbiol Infect; 2020 Jul; 26(7):818-823. PubMed ID: 31978546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine.
    Stasi C; Silvestri C; Voller F; Cipriani F
    J Infect Public Health; 2016; 9(4):389-95. PubMed ID: 26148849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.
    Easterbrook PJ;
    J Hepatol; 2016 Oct; 65(1 Suppl):S46-S66. PubMed ID: 27641988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    Hézode C
    J Viral Hepat; 2017 Feb; 24(2):92-101. PubMed ID: 27862695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urgency to treat patients with chronic hepatitis C in Asia.
    Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
    J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?
    Rosen HR
    Hepatology; 2017 Jan; 65(1):341-349. PubMed ID: 27640881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the Hepatitis C control plan in Qatar.
    Derbala M; Abd Farag E; Al-Romaihi H; Al Kaabi S; Al-Thani M; El Sayed E; Amer A; Himatt S
    East Mediterr Health J; 2019 Jul; 25(5):362-365. PubMed ID: 31364761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges.
    Zeisel MB; Lupberger J; Fofana I; Baumert TF
    J Hepatol; 2013 Feb; 58(2):375-84. PubMed ID: 23041307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV burden in Europe and the possible impact of current treatment.
    Mathurin P
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S314-7. PubMed ID: 24091109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
    Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
    J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On a straight path to HCV elimination in children - new prospects for hepatitis C treatment in Poland.
    Pluta M; Pokorska-Śpiewak M; Aniszewska M; Marczyńska M
    Przegl Epidemiol; 2020; 74(4):662-666. PubMed ID: 33861033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral hepatitis C.
    Czepiel J; Biesiada G; Mach T
    Pol Arch Med Wewn; 2008 Dec; 118(12):734-40. PubMed ID: 19202952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C therapy: Looking toward interferon-sparing regimens.
    Au TH; Destache CJ; Vivekanandan R
    J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global elimination of hepatitis C virus by 2030: why not?
    Dore GJ; Martinello M; Alavi M; Grebely J
    Nat Med; 2020 Feb; 26(2):157-160. PubMed ID: 32047317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.